← United States · Coverage record
US · SEC FORM 4
Adverum Biotechnologies, Inc.
ADVM · — · CIK 0001501756 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-08 · Fischer Laurent.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context capture is under review for ADVM. Last attempt: 2026-10-18T21:13:29.657793+00:00. —
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-08 | Fischer Laurent | Purchase (P) | Common Stock | 117,614 | USD 4.31 | USD 506,916 | SEC filing ↗ |
| 2025-12-05 | Soparkar Peter | Purchase (P) | Common Stock | 50,000 | USD 4.22 | USD 211,000 | SEC filing ↗ |
| 2025-12-05 | Fischer Laurent | Purchase (P) | Common Stock | 11,085 | USD 4.24 | USD 47,000 | SEC filing ↗ |
| 2025-04-23 | Leonard Braden Michael | Purchase (P) | Common Stock | 50,000 | USD 2.98 | USD 149,000 | SEC filing ↗ |
| 2025-04-22 | Leonard Braden Michael | Purchase (P) | Common Stock | 300,000 | USD 3.00 | USD 900,000 | SEC filing ↗ |
| 2025-04-02 | Leonard Braden Michael | Purchase (P) | Common Stock | 15,209 | USD 4.04 | USD 61,444 | SEC filing ↗ |
| 2025-03-31 | Leonard Braden Michael | Purchase (P) | Common Stock | 19,566 | USD 4.38 | USD 85,699 | SEC filing ↗ |
| 2025-03-27 | Leonard Braden Michael | Purchase (P) | Common Stock | 16,593 | USD 5.19 | USD 86,118 | SEC filing ↗ |
| 2025-03-27 | Leonard Braden Michael | Purchase (P) | Common Stock | 16,593 | USD 5.19 | USD 86,118 | SEC filing ↗ |
| 2025-03-27 | Leonard Braden Michael | Purchase (P) | Common Stock | 16,593 | USD 5.19 | USD 86,118 | SEC filing ↗ |
| 2025-03-26 | Leonard Braden Michael | Purchase (P) | Common Stock | 20,407 | USD 5.04 | USD 102,851 | SEC filing ↗ |
| 2025-03-26 | Leonard Braden Michael | Purchase (P) | Common Stock | 20,407 | USD 5.04 | USD 102,851 | SEC filing ↗ |
| 2025-03-26 | Leonard Braden Michael | Purchase (P) | Common Stock | 20,407 | USD 5.04 | USD 102,851 | SEC filing ↗ |
| 2025-03-20 | Leonard Braden Michael | Purchase (P) | Common Stovk | 30,600 | USD 5.61 | USD 171,666 | SEC filing ↗ |
| 2025-03-19 | Leonard Braden Michael | Purchase (P) | Common Stock | 25,000 | USD 4.94 | USD 123,500 | SEC filing ↗ |
Form 4 evidence
33 transaction lines in the latest 365-day window; 152 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | Svoronos Dawn | U (U) | Common Stock | 5,000 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Restricted Stock Units | 13,125 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Performance Stock Units | 157,333 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | Svoronos Dawn | U (U) | Common Stock | 5,000 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Restricted Stock Units | 13,125 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Performance Stock Units | 157,333 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock | 80,189 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Soparkar Peter | Award / grant (A) | Common Stock - Performance Stock Units | 150,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-09 | Seyedkazemi Setareh | U (U) | Common Stock - Restricted Stock Units | 8,125 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Seyedkazemi Setareh | U (U) | Common Stock - Performance Stock Units | 88,332 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Seyedkazemi Setareh | U (U) | Common Stock | 54,874 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Seyedkazemi Setareh | Award / grant (A) | Common Stock - Performance Stock Units | 85,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-09 | Scopa James Paul | U (U) | Common Stock | 10,333 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Rubinstein Linda M | U (U) | Common Stock - Restricted Stock Units | 8,125 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Rubinstein Linda M | U (U) | Common Stock - Performance Stock Units | 42,000 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Rubinstein Linda M | U (U) | Common Stock | 61,150 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Rubinstein Linda M | Option exercise / conversion (M) | Common Stock | 48,750 | USD 4.20 | USD 204,750 | SEC filing ↗ |
| 2025-12-09 | Rubinstein Linda M | Award / grant (A) | Common Stock - Performance Stock Units | 42,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-09 | Ozden Rabia Gurses | U (U) | Common Stock - Restricted Stock Units | 8,125 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Ozden Rabia Gurses | U (U) | Common Stock - Performance Stock Units | 85,000 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Ozden Rabia Gurses | Award / grant (A) | Common Stock - Performance Stock Units | 85,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-09 | Machado Patrick | U (U) | Common Stock | 8,818 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Lupher, Jr. Mark L. | U (U) | Common Stock | 13,000 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Fischer Laurent | U (U) | Common Stock - Restricted Stock Units | 25,000 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Fischer Laurent | U (U) | Common Stock - Performance Stock Units | 522,666 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Fischer Laurent | U (U) | Common Stock | 351,513 | USD — | USD — | SEC filing ↗ |
| 2025-12-09 | Fischer Laurent | Option exercise / conversion (M) | Common Stock | 150,000 | USD 4.20 | USD 630,000 | SEC filing ↗ |
| 2025-12-09 | Fischer Laurent | Award / grant (A) | Common Stock - Performance Stock Units | 500,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-09 | FHMLSP, L.L.C.; FHMLSP, L.P.; Frazier Life Sciences Public Fund, L.P. | U (U) | Common Stock | 4,288,949 | USD 3.56 | USD 15,268,658 | SEC filing ↗ |
| 2025-12-08 | Fischer Laurent | Purchase (P) | Common Stock | 117,614 | USD 4.31 | USD 506,916 | SEC filing ↗ |
| 2025-12-05 | Soparkar Peter | Purchase (P) | Common Stock | 50,000 | USD 4.22 | USD 211,000 | SEC filing ↗ |
| 2025-12-05 | Fischer Laurent | Purchase (P) | Common Stock | 11,085 | USD 4.24 | USD 47,000 | SEC filing ↗ |
| 2025-12-04 | Leonard Braden Michael | Sale (S) | Common Stock | 524,560 | USD 4.19 | USD 2,197,906 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ADVM |
| CIK | 0001501756 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | — |
Data coverage
| Local Form 4 history | 152 transaction lines from 2020-01-15 to 2025-12-09 45 P purchase lines · 42 S sale lines · 65 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.